George Bickerstaff is currently co-founder and Managing Director of M.M. Dillon & Co., a leading healthcare and technology boutique investment bank.
Prior to co-founding M.M. Dillon, he had a successful career as a corporate executive in the technology and healthcare industries, most notably as the Chief Financial Officer of Novartis Pharma AG.
He currently serves on the Boards of Innoviva and CareDx, and has previously served on the Boards of Axovant Sciences, Inovio and ARIAD, which was acquired by Takeda for $5.2 billion in 2017.
Mr. Bickerstaff brings extensive financial and operation experience in the healthcare, pharmaceutical and information technology industries, along with expertise in accounting and regulatory matters. He also provides strategic insights into the views of shareholders, investors, analysts, and others in the financial community.
George’s philanthropic interests are in global healthcare and child protection. He is currently the Chairman of the Board of Trustees of the International Vaccine Institute and Vice Chairman of the Board of the International Centre for Missing and Exploited Children.
George holds degrees in engineering and business administration from Rutgers University and Executive Education credentials from Harvard Business School.